The anti-depressant panel is part of the lab’s RxMatch series, which leverages pharmacogenomics, the study of how genetics affect an individual’s drug response. Intermountain Precision Genomics will pilot the panel in southwest Utah to enable physicians to apply personalized medicine when prescribing medications.
The RxMatch Anti-Depressant Panel is powered by clinical decision support from CNSDose, a startup that uses genetic testing to identify relevant antidepressant medications. With the DNA panel, a physician can use knowledge of a patient’s genome to select antidepressant medications.
“The objective of the RxMatch project is to provide the most comprehensive and evidence-based information to the physician, thus decreasing the amount of time and money spent to achieve the correct medication,” said David Loughmiller, laboratory manager for Intermountain Precision Genomics.
More articles on data analytics & precision medicine:
UC Davis to use precision medicine in pancreatic cancer care
Kalorama: Apple, Google, IBM make waves in healthcare analytics market
Intermountain, U of Utah Health to develop EHR clinical decision support under $3.8M NCI grant
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.